Superior efficacy of new medicines?

European Journal of Clinical Pharmacology

Volumn 66, Issue 5, 2010, Pages 445-448

  Van Luijn, Johan C F ^a,b   Gribnau, Frank W J ^c   Leufkens, Hubert G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Health Care Insurance Board ^*  (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Added therapeutic value; Comparative information; Market authorisation; Randomised active control trials; Superiority trials

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMPHOTERICIN B; BIMATOPROST; CAPECITABINE; EMTRICITABINE; ENOXAPARIN; FLUOROURACIL; FOLINIC ACID; FONDAPARINUX; HUMAN INSULIN; INSULIN ASPART; INSULIN GLULISINE; LOPINAVIR; NELFINAVIR; NEW DRUG; PAMIDRONIC ACID; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; STAVUDINE; TIMOLOL; TIPRANAVIR; TRAVOPROST; VORICONAZOLE; ZOLEDRONIC ACID;

ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; GLAUCOMA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INVASIVE ASPERGILLOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; COMPARATIVE STUDY; DRUG DEVELOPMENT; TREATMENT OUTCOME;

DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77954509209     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0808-3     Document Type: Article

References (18)

1. Dent TH, Hawke S (1997) Too soon to market. Br Med J 315:1248-1249
2. Gale EA, Clark A (2000) A drug on the market. Lancet 355:61-63
3. Henry D, Hill S (1995) Comparing treatments. Br Med J 310:1279
4. International Society of Drug Bulletins (2001) ISDB declaration on therapeutic advance in the use of medicines. International Society of Drug Bulletins, Paris
5. Lewis JA, Jonsson B, Kreutz G, Sampaio C, van Zwieten-Boot B (2002) Placebo-controlled trials and the Declaration of Helsinki. Lancet 359:1337-1340
6. The European Agency for the Evaluation of Medicinal Products (2000) Note for guidance on choice of control group in clinical trials (CPMP/ICH/364/96). EMEA, London
7. Koopmans PP, de Graeff PA, Zwieten-Boot BJ, Lekkerkerker JF, Broekmans AW (2000) Clinical evaluation of efficacy and adverse effects in the (European) registration of drugs: what does it mean for the doctor and the patient? (in Dutch). Ned Tijdschr Geneeskd 144:756-761
8. van Luijn JCF, Gribnau FW, Leufkens HG (2007) Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. Br J Clin Pharmacol 63:159-162
9. The European Agency for the Evaluation of Medicinal Products (2009) European Public Assessment Reports. Available at: http://www.emea.europa.eu/ htms/human/epar/eparintro.htm. Accessed Oct 2009
10. Kaplan W (2004) Comparative effectiveness of medicines and use of head-to-head comparative trials In: Kaplan W (2004) Priority medicines for Europe and the world. Ministry of Health, Welfare and Sport, The Hague
11. Van De Werf F, Adgey J, Ardissino D et al (1999) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354:716-722
12. van Luijn JCF, van Loenen AC, Gribnau FWJ, Leufkens HGM (2008) Choice of comparator in active control trials of new drugs. Ann Pharmacother 42:1605-1612
13. Heit JA (2002) The potential role of fondaparinux as venous thromboembolism prophylaxis after total hip or knee replacement or hip fracture surgery. Arch Intern Med 162:1806-1808
14. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162:1833-1840
15. Heerdink ER, Urquhart J, Leufkens HG (2002) Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf 11:447-453
16. Wathen B, Dean T (2004) An evaluation of the impact of NICE guidance on GP prescribing. Br J Gen Pract 54:103-107
17. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L (2000) Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23:583-588
18. Plank J, Wutte A, Brunner G et al (2002) A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 25:2053-2057